Battle of Honey Springs

Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication[1] formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[2]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[3]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[4]

References

  1. ^ Citrome L (November 2013). "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach". CNS Drugs. 27 (11): 879–911. doi:10.1007/s40263-013-0105-7. PMID 24062193. S2CID 23867019.
  2. ^ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Archived from the original on 2 February 2017. Retrieved 6 February 2014.
  3. ^ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Archived from the original on 8 October 2016. Retrieved 6 February 2014.
  4. ^ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Archived from the original (PDF) on 18 June 2015. Retrieved 18 June 2015.

External links


source: https://en.wikipedia.org/wiki/Zicronapine